Doxorubicin plus sorafenib in treatment of advanced hepatocellular carcinoma

JAMA. 2011 Feb 23;305(8):781; author reply 781. doi: 10.1001/jama.2011.159.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / therapeutic use*
  • Benzenesulfonates / therapeutic use
  • Carcinoma, Hepatocellular / drug therapy*
  • Disease Progression
  • Doxorubicin / therapeutic use*
  • Endpoint Determination
  • Humans
  • Liver Neoplasms / drug therapy*
  • Niacinamide / analogs & derivatives
  • Phenylurea Compounds
  • Prognosis
  • Pyridines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Reproducibility of Results
  • Sorafenib
  • Treatment Outcome

Substances

  • Antineoplastic Agents
  • Benzenesulfonates
  • Phenylurea Compounds
  • Pyridines
  • Niacinamide
  • Doxorubicin
  • Sorafenib